GCG and obesity disorder: Similar findings regarding weight loss plateaus or weight regain have been observed with the GLP1-GIP receptor dual agonist Tirzepatide (The SURMOUNT-4 Randomized Clinical Trial, NCT04660643), GLP1-glucagon receptor dual agonist Mazdutide (First Phase 3 Clinical Trial of Mazdutide, NCT05607680), and GLP1-GIP-glucagon tri-agonist Retatrutide (Phase 2 Trial of Retatrutide for Obesity, NCT04881760).